What is Paratus Sciences?
Paratus Sciences operates as a specialized biotechnology entity headquartered in New York, New York. The company is primarily engaged in the rigorous application of animal studies to facilitate drug discovery and therapeutic validation. By bridging the gap between foundational biological research and clinical application, Paratus Sciences occupies a critical niche in the pharmaceutical development ecosystem. Its market position is defined by a commitment to high-fidelity data generation and the translation of complex biological insights into actionable medical solutions, serving as a vital partner for organizations seeking to de-risk early-stage drug development programs.
How much funding has Paratus Sciences raised?
Paratus Sciences has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2023): $100M with participation from ClavystBio, Polaris Partners, and ARCH Venture Partners
Key Investors in Paratus Sciences
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and strategic guidance.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups to commercialize innovations.
ClavystBio
ClavystBio is a venture investor focused on accelerating the commercialization of life sciences innovations, providing the necessary capital and network to scale high-impact biotechnology ventures.
What's next for Paratus Sciences?
With the successful closure of this major strategic investment, Paratus Sciences is poised to enter a phase of aggressive growth and infrastructure expansion. The company is expected to utilize these resources to enhance its laboratory capabilities and expand its team of specialized scientists and researchers. Future milestones will likely include the scaling of its animal study platforms and the potential initiation of new collaborative research agreements with academic and corporate partners. By maintaining a disciplined approach to capital allocation, Paratus Sciences aims to solidify its reputation as a leader in the biotechnology sector, ultimately driving long-term value for its stakeholders and contributing to the advancement of global health outcomes.
See full Paratus Sciences company page
